• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨噬细胞移动抑制因子的血清水平与类风湿关节炎的病程相关。

Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.

机构信息

Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada #950, Col. Independencia, 44348 Guadalajara, Jalisco, Mexico.

出版信息

Rheumatol Int. 2012 Aug;32(8):2307-11. doi: 10.1007/s00296-011-1951-6. Epub 2011 May 24.

DOI:10.1007/s00296-011-1951-6
PMID:21607559
Abstract

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of unknown etiology. Many cytokines have been found to be associated with RA pathogenesis and among them is macrophage migration inhibitory factor (MIF). The aim of this study was to determine whether MIF serum levels are associated with RA course, clinical activity, and clinical biomarkers of the disease. MIF levels were determined in serum samples of 54 RA patients and 78 healthy subjects (HS) by enzyme-linked immunosorbent assay (ELISA). Disease activity was evaluated using the DAS28 score. Patients were subgrouped according to disease activity and years of evolution of disease. Statistical analysis was carried out by SPSS 10.0 and GraphPad Prism 5 software. RA patients presented increased levels of MIF as compared to HS. MIF levels were raised on early stages of RA and tend to decrease according to years of evolution. Moreover, MIF levels positively correlated with rheumatoid factor in RA patients and with C reactive protein in all individuals studied. Our findings suggest that MIF plays a role in early stages of RA.

摘要

类风湿关节炎(RA)是一种病因不明的炎症性自身免疫性疾病。许多细胞因子已被发现与 RA 的发病机制有关,其中包括巨噬细胞移动抑制因子(MIF)。本研究旨在确定 MIF 血清水平是否与 RA 病程、临床活动和疾病的临床生物标志物有关。采用酶联免疫吸附试验(ELISA)法检测 54 例 RA 患者和 78 例健康对照者(HS)血清样本中的 MIF 水平。采用 DAS28 评分评估疾病活动度。根据疾病活动度和疾病演变年限将患者分组。采用 SPSS 10.0 和 GraphPad Prism 5 软件进行统计学分析。与 HS 相比,RA 患者的 MIF 水平升高。MIF 水平在 RA 的早期阶段升高,并随着疾病的演变而趋于降低。此外,MIF 水平与 RA 患者的类风湿因子呈正相关,与所有研究个体的 C 反应蛋白呈正相关。我们的研究结果表明,MIF 在 RA 的早期阶段发挥作用。

相似文献

1
Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.巨噬细胞移动抑制因子的血清水平与类风湿关节炎的病程相关。
Rheumatol Int. 2012 Aug;32(8):2307-11. doi: 10.1007/s00296-011-1951-6. Epub 2011 May 24.
2
MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.使用改善病情抗风湿药物治疗的类风湿关节炎患者的血清MIF和TNFα水平:一项横断面研究。
Immunopharmacol Immunotoxicol. 2015 Apr;37(2):207-13. doi: 10.3109/08923973.2015.1017645. Epub 2015 Feb 27.
3
Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis.巨噬细胞移动抑制因子(MIF):参与早发性和早期类风湿关节炎的遗传证据。
Cytokine. 2013 Mar;61(3):759-65. doi: 10.1016/j.cyto.2012.12.032. Epub 2013 Feb 9.
4
Elevated serum levels of macrophage migration inhibitory factor and their significant correlation with rheumatoid vasculitis disease activity.血清巨噬细胞移动抑制因子水平升高及其与类风湿性血管炎疾病活动的显著相关性。
Mod Rheumatol. 2012 Feb;22(1):59-65. doi: 10.1007/s10165-011-0466-z. Epub 2011 May 24.
5
Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico.巨噬细胞移动抑制因子启动子多态性与来自墨西哥南部的类风湿关节炎患者的疾病活动相关。
Mol Genet Genomic Med. 2020 Jan;8(1):e1037. doi: 10.1002/mgg3.1037. Epub 2019 Nov 7.
6
Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.类风湿关节炎患者接受抗肿瘤坏死因子治疗后血脂谱和巨噬细胞移动抑制因子水平的持续变化
Ann Rheum Dis. 2009 Aug;68(8):1316-21. doi: 10.1136/ard.2007.086728. Epub 2008 Aug 22.
7
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.类风湿关节炎严重程度与巨噬细胞移动抑制因子的基因功能变异及循环水平的相关性
Arthritis Rheum. 2005 Oct;52(10):3020-9. doi: 10.1002/art.21285.
8
Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between gene polymorphisms and disease susceptibility: a meta-analysis.循环巨噬细胞移动抑制因子 (MIF) 水平与类风湿关节炎的相关性,以及基因多态性与疾病易感性的相关性:一项荟萃分析。
Postgrad Med J. 2018 Feb;94(1108):109-115. doi: 10.1136/postgradmedj-2017-134934. Epub 2017 Sep 14.
9
Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis.巨噬细胞移动抑制因子:类风湿关节炎的潜在治疗靶点。
Korean J Intern Med. 2016 Jul;31(4):634-42. doi: 10.3904/kjim.2016.098. Epub 2016 May 12.
10
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.巨噬细胞移动抑制因子基因多态性不能预测类风湿关节炎患者对糖皮质激素或肿瘤坏死因子α中和治疗的反应。
Ann Rheum Dis. 2007 Nov;66(11):1525-30. doi: 10.1136/ard.2006.064394. Epub 2007 Apr 24.

引用本文的文献

1
Macrophage migration inhibitory factor: Exploring physiological roles and comparing health benefits against oncogenic and autoimmune risks (Review).巨噬细胞移动抑制因子:探索生理作用并比较其对致癌风险和自身免疫风险的健康益处(综述)
Int J Mol Med. 2025 Oct;56(4). doi: 10.3892/ijmm.2025.5590. Epub 2025 Jul 19.
2
Macrophage migration inhibitory factor reversed senescent phenotype in human chondrocytes in vitro.巨噬细胞移动抑制因子在体外逆转人软骨细胞的衰老表型。
Mol Biol Rep. 2024 Jan 21;51(1):154. doi: 10.1007/s11033-023-09101-0.
3
Expression of Transcriptional Factors of T Helper Differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF Receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 Cytokines in PBMC from Control Subjects and Rheumatoid Arthritis Patients.

本文引用的文献

1
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project.阿那白滞素治疗类风湿关节炎的疗效与安全性:俄勒冈药物疗效评估项目的更新
Biologics. 2009;3:485-98. doi: 10.2147/btt.2009.3755. Epub 2009 Dec 29.
2
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.抗白细胞介素-6受体单克隆抗体托珠单抗单药治疗类风湿关节炎患者的长期安全性和疗效(STREAM研究):一项5年延长期研究的安全性和疗效证据
Ann Rheum Dis. 2009 Oct;68(10):1580-4. doi: 10.1136/ard.2008.092866. Epub 2008 Nov 19.
3
来自对照受试者和类风湿性关节炎患者外周血单个核细胞中辅助性T细胞分化转录因子(T-bet、GATA-3、RORγt和FOXP3)、巨噬细胞移动抑制因子受体(CD44、CD74、CXCR2、4、7)以及Th1、Th2和Th17细胞因子的表达
Curr Mol Med. 2024;24(9):1169-1182. doi: 10.2174/0115665240260976230925095330.
4
Association of Macrophage Migration Inhibitory Factor Gene -173 G/C Polymorphism (rs755622) with Familial Mediterranean Fever in Children.巨噬细胞移动抑制因子基因-173 G/C多态性(rs755622)与儿童家族性地中海热的关联
J Pediatr Genet. 2020 Nov 25;11(2):91-98. doi: 10.1055/s-0040-1719053. eCollection 2022 Jun.
5
Molecular Level Insights Into the Structural and Dynamic Factors Driving Cytokine Function.驱动细胞因子功能的结构和动态因素的分子水平见解
Front Mol Biosci. 2021 Oct 25;8:773252. doi: 10.3389/fmolb.2021.773252. eCollection 2021.
6
Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico.巨噬细胞抑制因子(MIF)基因多态性与墨西哥西部活动非节段性白癜风患者的疾病易感性和循环 MIF 水平相关。
Mol Genet Genomic Med. 2020 Oct;8(10):e1416. doi: 10.1002/mgg3.1416. Epub 2020 Jul 23.
7
Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico.巨噬细胞移动抑制因子启动子多态性与来自墨西哥南部的类风湿关节炎患者的疾病活动相关。
Mol Genet Genomic Med. 2020 Jan;8(1):e1037. doi: 10.1002/mgg3.1037. Epub 2019 Nov 7.
8
Macrophage Migration Inhibitory Factor Levels in Gingival Crevicular Fluid, Saliva, and Serum of Chronic Periodontitis Patients.慢性牙周炎患者龈沟液、唾液和血清中巨噬细胞移动抑制因子水平。
Biomed Res Int. 2019 Feb 5;2019:7850392. doi: 10.1155/2019/7850392. eCollection 2019.
9
Macrophage migration inhibitory factor polymorphisms are a potential susceptibility marker in systemic sclerosis from southern Mexican population: association with MIF mRNA expression and cytokine profile.巨噬细胞移动抑制因子多态性是来自墨西哥南部人群的系统性硬化症的潜在易感标志物:与 MIF mRNA 表达和细胞因子谱相关。
Clin Rheumatol. 2019 Jun;38(6):1643-1654. doi: 10.1007/s10067-019-04459-8. Epub 2019 Feb 12.
10
mRNA Expression and Soluble Levels in Acute Coronary Syndrome.急性冠状动脉综合征中的mRNA表达与可溶性水平
Cardiol Res Pract. 2018 Jul 2;2018:9635652. doi: 10.1155/2018/9635652. eCollection 2018.
Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis.
巨噬细胞移动抑制因子:类风湿关节炎、系统性红斑狼疮和动脉粥样硬化中的关键细胞因子。
Clin Chim Acta. 2009 Jan;399(1-2):1-7. doi: 10.1016/j.cca.2008.09.014. Epub 2008 Sep 21.
4
Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility.巨噬细胞移动抑制因子基因:对类风湿关节炎易感性的影响。
Hum Immunol. 2007 Sep;68(9):744-7. doi: 10.1016/j.humimm.2007.06.007. Epub 2007 Jul 27.
5
Cytokines in the pathogenesis of rheumatoid arthritis.细胞因子在类风湿关节炎发病机制中的作用
Nat Rev Immunol. 2007 Jun;7(6):429-42. doi: 10.1038/nri2094.
6
Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome.原发性干燥综合征患者血清巨噬细胞移动抑制因子水平升高。
Arthritis Res Ther. 2007;9(2):R43. doi: 10.1186/ar2182.
7
A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis.一种靶向巨噬细胞移动抑制因子的新型DNA疫苗可保护小鼠关节炎模型的关节免受炎症和破坏。
Arthritis Rheum. 2007 Feb;56(2):521-30. doi: 10.1002/art.22407.
8
The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes.巨噬细胞移动抑制因子对原代人肝细胞急性期蛋白产生的影响。
Int J Mol Med. 2006 Nov;18(5):957-61.
9
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.类风湿关节炎严重程度与巨噬细胞移动抑制因子的基因功能变异及循环水平的相关性
Arthritis Rheum. 2005 Oct;52(10):3020-9. doi: 10.1002/art.21285.
10
Macrophage migration inhibitory factor and its role in autoimmune diseases.巨噬细胞移动抑制因子及其在自身免疫性疾病中的作用。
Arch Immunol Ther Exp (Warsz). 2004 Nov-Dec;52(6):389-400.